Cüneyt TAYMAN, Ufuk ÇAKIR, Özdemir ÖZDEMİR

Prematür retinopatisinin tanısı ve lazer tedavisine cevabın takibinde VEGF ve IGF-1’in değeri

Amaç: Prematüre retinopatisinin (ROP) erken tanınması, zamanında ve uygun tedavisi, bebeğin gelişim sürecine katkıda bulunacak ve görme kaybını önleyerek yaşam kalitesini artıracaktır. Biz burada lazer tedavisi gerektiren şiddetli ROP olan bebeklerde vasküler endotelyal büyüme faktörü (VEGF) ve insülin benzeri büyüme faktörü-1'in (IGF-1) kan düzeylerinin değerini belirlemeyi amaçladık.Gereç ve Yöntem: Çok düşük doğum ağırlıklı bebekler (ÇDDA, ≤1500 g ve gestasyonel yaş ≤32 hafta) çalışmaya alındı. ROP ve kontrol grubu için tüm pretermler için doğumdan itibaren ve aynı doğum sonrası düzeltilmiş yaşta (34 hafta) belirteçlerin değerlendirilmesi için kan örnekleri alındı.Bulgular: Kontrol grubunda ortalama serum VEGF düzeyi 185,6 ± 88,1 pg / mL ve ROP grubunda lazer tedavisi öncesi 590,2 ± 97,4 pg / mL idi. ROP grubunda lazer tedavisinden 4 gün sonra 83,7 ± 25,4 pg / mL'ye düştü Şiddetli ROP'lu bebeklerde lazer tedavisi öncesi ve sonrasında IGF-1 değerleri arasında anlamlı fark yoktu. Sonuç: Serum VEGF ve IGF-1 seviyeleri, şiddetli ROP'un duyarlı bir belirteçleri olarak önerilebilir. Ek olarak, lazer tedavisinden sonra VEGF'nin serum seviyelerindeki azalma, lazer tedavisinin etkinliği için bir gösterge olarak kullanılabilir.

Anahtar Kelimeler:

insülin benzeri büyüme faktörü-1, prematürite retinopatisi, vasküler endotelyal büyüme faktörü

The value of VEGF and IGF-1 in the diagnosis retinopathy of prematurity and follow-up of response to laser therapy

Purpose: Early recognition of the retinopathy of prematurity (ROP), timely and appropriate treatment will contribute to the developmental process of the infant and increase the quality of life by preventing vision loss. We here by aimed to figure out the value of the blood levels of vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) in infants with severe ROP requiring laser therapy.Materials and Methods: Very low birth weight infants (VLBW, ≤1500 g and gestational age ≤32 weeks) were included in the study. Blood samples for the evaluation of markers were obtained from the cord at birth for all preterms and at the same postpartum corrected age (34 weeks) for ROP and control group.Results: The mean serum VEGF level was 185.6 ± 88.1 pg/mL in the control group and 590.2 ± 97.4 pg/mL before laser treatment in the ROP group . It was decreased to 83.7 ± 25.4 pg/mL at 4 day after laser treatment in the ROP group). No significant difference was existed between the values of IGF-1 before and after laser treatment in infants with severe ROP.Conclusion: Serum VEGF and IGF-1 levels may be suggested as a sensitive marker of severe ROP. Additionally, the decrease in serum levels of VEGF after laser therapy can be used as an indicator for the efficacy of laser treatment.

Keywords:

insulin-like growth factor-1, retinopathy of prematurity, vascular endothelial growth factor,

PDF

___

1. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367:2515-26.
2. Liegl R, Hellström A, Smith LE. Retinopathy of prematurity: the need for prevention. Eye Brain. 2016;8:91-102.
3. Hartnett ME. Pathophysiology and mechanisms of severe retinopathy of prematurity. Ophthalmology. 2015;122:200-10.
4. Sato T, Kusaka S, Shimojo H, Fujikado T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology. 2009;116:2165-9.
5. Hellström A, Engström E, Hård AL, AlbertssonWikland K, Carlsson B, Niklasson A et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics. 2003;112:1016-20.
6. Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL et al. Low IGF-I suppresses VEGFsurvival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A. 2001;98:5804-8.
7. Kliegman RM, Walsh MC. Neonatal necrotizing enterocolitis: pathogenesis, classification, and spectrum of illness. Curr Probl Pediatr. 1987;17:213- 88.
8. Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol. 2003;23:451-6.
9. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978;92:529-34.
10. International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123:991-9.
11. Shah PK, Prabhu V, Karandikar SS, Ranjan R, Narendran V, Kalpana N. Retinopathy of prematurity: Past, present and future. World J Clin Pediatr. 2016;5:35-46.
12. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol. 1988;106:471-9.
13. Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684- 94.
14. Darlow BA, Hutchinson JL, Henderson-Smart DJ, Donoghue DA, Simpson JM, Evans NJ; Australian and New Zealand Neonatal Network. Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics. 2005;115:990-6.
15. Podraza W, Michalczuk B, Jezierska K, Domek H, Kordek A, Łoniewska B et al. Correlation of Retinopathy of Prematurity with Bronchopulmonary Dysplasia. Open Med (Wars). 2018;13:67-73.
16. Heidary G, Vanderveen D, Smith LE. Retinopathy of prematurity: current concepts in molecular pathogenesis. Semin Ophthalmol. 2009;24:77-81.
17. Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008;49:5177-82.
18. Cavallaro G, Filippi L, Bagnoli P, La Marca G, Cristofori G, Raffaeli G et al. The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge. Acta Ophthalmol. 2014;92:2- 20.
19. Kwinta P, Bik-Multanowski M, Mitkowska Z, Tomasik T, Pietrzyk JJ. The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2008;246:1467-75.
20. Hellgren G, Löfqvist C, Hård AL, Hansen-Pupp I, Gram M, Ley D et al. Serum concentrations of vascular endothelial growth factor in relation to retinopathy of prematurity. Pediatr Res. 2016;79:70- 5.
21. Hellström A, Ley D, Hansen-Pupp I, Hallberg B, Ramenghi LA, Löfqvist C et al. Role of Insulinlike Growth Factor 1 in Fetal Development and in the Early Postnatal Life of Premature Infants. Am J Perinatol. 2016;33:1067-71.
22. Hellström A, Ley D, Hansen-Pupp I, Hallberg B, Ramenghi LA, Löfqvist C et al. IGF-I in the clinics: Use in retinopathy of prematurity. Growth Horm IGF Res. 2016;30-31:75-80.
23. Yalin Imamoglu E, Gunay M, Gursoy T, Imamoglu S, Balci Ekmekci O, Celik G et al. Effect of laser photocoagulation on plasma levels of VEGF-A, VEGFR-2, and Tie2 in infants with retinopathy of prematurity. J AAPOS. 2014;18:466-70.
24. Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ et al. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2015;56:956-61.